From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Routes of
Legal status
Legal status
  • Uncontrolled
Pharmacokinetic data
Biological half-life 2-3 hours
CAS Number 83928-76-1
ATC code N06AX19 (WHO)
PubChem CID 55191
Chemical data
Formula C19H29N5O2
Molar mass 359.46586 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Gepirone (Ariza, Variza; BMY-13,805, ORG-13,011) is a psychoactive drug and research chemical of the piperazine and azapirone chemical classes. It is currently under clinical development in an extended release form as an anxiolytic and antidepressant agent. Pharmacologically, gepirone acts as a selective 5-HT1A receptor partial agonist.

Gepirone was originally developed by Bristol-Myers Squibb, but was out-licensed to Fabre-Kramer in 1993. The U.S. Food and Drug Administration (FDA) rejected approval for gepirone in 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2004. However, in 2007 it once again failed to convince the FDA of its qualities for treating anxiety and depression. Fabre-Kramer and GlaxoSmithKline are evaluating the response from the FDA to determine appropriate next steps.[1]


Ormaza, V. A.; 1986, ES 8606333 .

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. Press release from GlaxoSmithKline